Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed risks related to its G6 and G7 continuous glucose monitoring systems during the specified Class Period from January 8, 2024, to September 17, 2025 [1][2]. Allegations Against DexCom - The complaints allege that DexCom made unauthorized design changes to its G6 and G7 systems, which compromised their reliability and posed health risks to users [2]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 device, downplaying the severity of issues related to adulterated devices [2]. - The allegations suggest that these actions increased DexCom's exposure to regulatory scrutiny and potential legal, reputational, and financial harm [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action, or they may choose to remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select legal counsel for the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Viewpoint - Rosen Law Firm is urging investors of DexCom, Inc. to take action before the December 29, 2025 deadline for a securities class action related to misleading statements made by the company during the class period from July 26, 2024, to September 17, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 29, 2025, and can do so by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4].

Core Viewpoint - The Rosen Law Firm is reminding investors of DexCom, Inc. about an important deadline related to a securities class action lawsuit, encouraging them to secure legal counsel before December 29, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [5]. - The defendants are accused of making false statements regarding the reliability and functionality of the G7 devices, leading to increased regulatory scrutiny and potential legal repercussions for DexCom [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - To join the class action, investors can visit the provided link or contact the firm directly for more information [3][6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3][5]. - The lawsuit claims that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which posed health risks to users [5]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom's design changes rendered the G6 and G7 systems less reliable, overstating the devices' enhancements and functionality [5]. - It is claimed that DexCom downplayed the severity of issues related to the G7 devices, which increased the risk of regulatory scrutiny and potential legal repercussions [5]. - The public statements made by DexCom during the Class Period are described as materially false and misleading, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Core Viewpoint - Class actions have been initiated on behalf of stockholders of DexCom, Inc. and Wildermuth Fund, with deadlines for investors to petition the court to serve as lead plaintiff [1]. DexCom, Inc. (NASDAQ:DXCM) - The class action alleges that during the class period from January 8, 2024, to September 17, 2025, DexCom made materially false and misleading statements regarding its business and compliance policies [6]. - Specific allegations include unauthorized design changes to the G6 and G7 devices that rendered them less reliable, presenting health risks to users [6]. - The complaint claims that the enhancements to the G7 were overstated and that the true scope of issues with the devices was downplayed, leading to increased regulatory scrutiny and potential legal and financial harm [6]. Wildermuth Fund (NASDAQ:WEFCX, NASDAQ:WESFX, NASDAQ:WEIFX) - The class action for Wildermuth Fund covers the period from November 1, 2020, to June 29, 2023, with a lead plaintiff deadline of December 29, 2025 [6]. - Allegations include miscalculating the fair value of the Fund's investments and failing to disclose financial support for portfolio companies with questionable viability [6]. - The complaint also states that the Fund intentionally inflated its net asset value, resulting in excessive advisory fees, which harmed class members [6].

Core Viewpoint - Rosen Law Firm is reminding investors of DexCom, Inc. about the upcoming deadline for a securities class action lawsuit, encouraging them to secure legal counsel before December 29, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 29, 2025, and can join by submitting a form or contacting the law firm [3][6]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues, leading to increased regulatory scrutiny and potential legal repercussions [5].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. alleging that the company made misleading statements regarding the reliability and safety of its G6 and G7 glucose monitoring devices, which were modified without FDA approval, leading to health risks for users [2][4]. Summary by Sections Lawsuit Details - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7 devices, which compromised their reliability and presented health risks to users [2]. - Allegations include overstating the enhancements and reliability of the G7, downplaying the severity of issues with the devices, and exposing the company to increased regulatory scrutiny and potential legal consequences [2]. Regulatory Concerns - On March 7, 2025, DexCom received a warning letter from the FDA regarding manufacturing and quality management issues, resulting in a share price drop of $7.12, or approximately 9.15%, from $77.84 to $70.72 [3]. - The FDA's published warning letter on March 25, 2025, confirmed that DexCom had adulterated its devices, leading to a further decline in share price by $1.77, or about 2.4%, from $75.32 to $73.55 [4]. Market Reactions - On September 8, 2025, Oppenheimer downgraded DexCom's rating to "perform" from "outperform," citing concerns over the G7's accuracy and performance, which caused a decline in share price by $2.51, or approximately 3.1%, from $80.51 to $78.00 [5]. - A report by Hunterbrook Media LLC on September 18, 2025, highlighted severe health risks associated with the G7 devices, linking them to hospitalizations and fatalities, resulting in a significant share price drop of $8.33, or about 11%, from $75.78 to $67.45 [7].

Core Viewpoint - Labaton Keller Sucharow LLP has filed a securities class action lawsuit against DexCom, Inc. and certain executives, alleging misleading statements regarding the reliability and safety of their continuous glucose monitoring systems [1][4]. Summary by Sections Lawsuit Details - The lawsuit was filed on November 25, 2025, on behalf of the Boston Retirement System against DexCom and its executives, asserting claims under the Securities Exchange Act of 1934 [1]. - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025 [1]. Allegations - The complaint alleges that DexCom made unauthorized design changes to its CGM products, which rendered them less reliable and posed health risks to users [4]. - It is claimed that these undisclosed issues led to increased regulatory scrutiny and negatively impacted the company's sales and public statements regarding product reliability [4]. Impact on Stock Price - Following disclosures about the accuracy problems of DexCom's CGM devices, the company's stock price fell by $8.99 per share, or 11.8%, closing at $67.45 on September 19, 2025 [5]. Legal Representation - The Boston Retirement System is represented by Labaton Keller Sucharow LLP, which has a strong reputation in securities litigation and manages over $4.5 trillion in assets [8].

Core Viewpoint - The Gross Law Firm is notifying shareholders of DexCom, Inc. regarding a class action lawsuit due to allegations of misleading statements and undisclosed material changes to their glucose monitoring products [1][3]. Group 1: Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes reportedly made the G6 and G7 devices less reliable, posing a material health risk to users who depend on accurate glucose readings [3]. - The enhancements claimed for the G7 device, including its reliability and accuracy, were allegedly overstated by the defendants [3]. - The true scope and severity of the issues related to the G7 devices were downplayed, increasing the risk of regulatory scrutiny and potential legal and financial repercussions for DexCom [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025, with a deadline for shareholders to register for the class action set for December 26, 2025 [3][4]. - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors who have suffered losses due to misleading statements or omissions [5].

Core Viewpoint - Ademi & Fruchter LLP is investigating potential securities fraud claims against DexCom, Inc. due to inaccurate statements regarding its business operations and the quality of its products [1][2]. Group 1: Investigation Details - The investigation centers on DexCom's claims about its G7 blood glucose monitor, asserting it was of high quality and manufactured with FDA-approved materials [2]. - Reports indicate that DexCom altered the sensor membrane coating material from a third-party supplier to an in-house formulation without notifying the FDA or investors, which deviated from the FDA-approved formulation [2]. - The investigation period spans from January 8, 2024, to September 17, 2025 [2].